Floatz logo

cd19/cd22-car-transduced t cells

B-precursor ALL

National Cancer Institute (NCI)Cell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the B-precursor ALL cohort.

Asset / SponsorPhaseRating
Fludarabine
National Cancer Institute (NCI)
Phase 2/3BB
cd22 car-transduced t cells
National Cancer Institute (NCI)
Phase 1CCC

Same molecule, other indications

cd19/cd22-car-transduced t cells is also rated in:

Leukemia, Lymphocytic, B CellDormant
CCC
Indicative ·
48 / 100
View asset →
B-AllDormant
CC
Indicative ·
47 / 100
View asset →
B-Cell LymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →